Azacitadine Plus Pevonedistat Shows Efficacy in MDS/CMML or LB AML
June 23rd 2020Mikkael Sekeres, MD, discusses a phase 2 study of pevonedistat plus azacitidine versus azacitadine monotherapy in patients with higher-risk myelodysplastic syndromes /chronic myelomonocytic leukemia or low-blast acute myelogenous leukemia.